You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In PLOS this week: chromosomal integration of human herpesvirus 6, gene expression predictions across populations, and more.
In PLOS this week: method to detect SARS-CoV-2 directly from swabs, gene expression patterns in Kaposi's sarcoma, and more.
The firm said that with this clearance it now provides a comprehensive menu of VZV and HSV tests from swab and cerebrospinal fluid specimens.
The Simplexa VZV Swab Direct runs on the firm's Liason MDX instrument and has also been submitted to the US Food and Drug Administration.
The firm said that its HSV and varicella-zoster virus assay delivers answers for related herpes conditions in about an hour.
The company plans to take a tiered approach to assay development, targeting its first test to 10 viruses commonly detected in transplant patients.
The fully automated system has 12 independent thermal cyclers and runs the firm's diagnostic kits, but it can also operate as an open instrument.
Using omics and other data, researchers performed network analyses that pointed to interactions between human herpesviruses and other Alzheimer's disease risk factors.
With the new clearance, DiaSorin's test can be run on genital swabs, and all cutaneous and mucocutaneous swab samples, as well as CSF samples.
Smithsonian reports that some researchers are turning to gene editing to target established infections like herpes.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.